Aptevo Therapeutics Inc. filed a Form 8-K on September 24, 2026, disclosing progress in its next-generation trispecific programs and announcing an expected timeline for IND-enabling studies for its lead candidate, APVO451.
Key Highlights
- Trispecific program update: Aptevo disclosed progress in its next-generation trispecific programs, according to the filing.
- Manufacturing optimization: The company is optimizing several trispecific candidates for "reliable, scalable manufacturing," described as "an essential step toward future human testing."
- Lead candidate: The lead candidate is identified as APVO451.
- IND-enabling study timeline: Aptevo expects to enter Investigational New Drug enabling studies for APVO451 in the first half of 2027.
- Exchange listing: Aptevo's common stock ($0.001 par value) trades under the symbol APVO on NASDAQ:APVO.
Aptevo Therapeutics Reports Trispecific Pipeline Milestone and APVO451 Development Plan
On September 24, 2026, Aptevo Therapeutics Inc. issued a press release, attached as Exhibit 99.1 to an 8-K filing, announcing updates on its next-generation trispecific programs. According to the filing, the company is currently optimizing several trispecific candidates with the stated goal of achieving "reliable, scalable manufacturing," which the company characterized as "an essential step toward future human testing."
The filing identifies APVO451 as the lead candidate within the trispecific pipeline. Aptevo disclosed that it expects to enter Investigational New Drug enabling studies for APVO451 in the first half of 2027. The filing does not specify additional clinical timelines, financial figures, or partnership details beyond this disclosure.
The 8-K was signed by Daphne Taylor, Senior Vice President and Chief Financial Officer of Aptevo Therapeutics Inc., and was filed under Item 8.01 (Other Events). Aptevo is incorporated in Delaware and maintains its principal executive offices at 2401 4th Avenue, Suite 1050, Seattle, Washington 98121. The company's common stock is registered under Section 12(b) of the Securities Exchange Act of 1934.
What Was Disclosed
Aptevo Therapeutics filed an 8-K on September 24, 2026, reporting progress in its trispecific programs and stating that IND-enabling studies for lead candidate APVO451 are expected to begin in the first half of 2027.



Please wait processing your request...